Auranofin/Mometasone furoate

莫米松糠酸酯/金诺芬

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAuranofin/Mometasone furoate
Drug Alias NameMometasone furoate+Auranofin莫米松糠酸酯+金诺芬金诺芬/莫米松糠酸酯Auranofin+Mometasone furoate金诺芬+莫米松糠酸酯 +[6] 
ClassificationSmall molecules > Steroids
Mechanisms of ActionInhibitor of NF-kappa-B kinase (IKK) inhibitorsGlucocorticoid receptor agonists
TargetsGlucocorticoid receptorInhibitor of NF-kappa-B kinase (IKK)
Therapy Area/IndicationsDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes AuranofinMometasone furoate
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesViralytics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesViralytics Ltd
Active IndicationsN/A
Inactive IndicationsDermatitis, Atopic

Other Information

ATC CodeN/A
Related LinksN/A